Attention medical professionals: A new pharmaceutical product, Cefepime powder for preparing a solution for intramuscular injection, has been registered.
31.01.2017
Attention medical professionals: A new pharmaceutical product, Cefepime powder for preparing a solution for intramuscular injection, has been registered.
Cefepime is a semi-synthetic antibiotic belonging to the fourth generation of cephalosporins. Cefepime exhibits a broad spectrum of antimicrobial activity, covering both gram-positive and gram-negative aerobic bacteria as well as some anaerobes. The drug has a unique mechanism of action: its molecule penetrates the porin channels into the periplasmic space seven times faster than cefotaxime and ceftriaxone, binding to target sites and preventing premature degradation by circulating beta-lactamases. An important feature of cefepime is its low affinity for beta-lactamases, which makes it effective against beta-lactamase-producing resistant bacteria.
Due to the widespread presence of beta-lactamase-producing strains of gram-negative bacteria resistant to first- to third-generation cephalosporins, cefepime holds a leading position as a hospital antibiotic.
According to data obtained in vivo and from healthy volunteers, 100% of cefepime is absorbed into the systemic circulation when administered intramuscularly. This significantly optimizes therapy compliance and reduces treatment costs, as intravenous injections or infusions require qualified personnel and equipment and are not always convenient in general medical wards outside of intensive care units. Additionally, there is a risk of serious procedural complications.
The pharmaceutical product Cefepime powder for preparing a solution for intramuscular injection, manufactured by PJSC “Kraspharma,” is designed to optimize antibiotic therapy in hospital settings, bringing the benefits of modern antimicrobial drugs to broader clinical practice.
The drug is indicated for use in adults for:
In children aged 12-18 years, the following indications are approved:
To prevent the development of pain associated with intramuscular injection, the Cefepime powder for preparing a solution for intramuscular injection manufactured by PJSC “Kraspharma” is available in combination with a solvent – lidocaine injection solution 10 mg/ml, 3.5 ml in a glass ampoule.
Due to the widespread presence of beta-lactamase-producing strains of gram-negative bacteria resistant to first- to third-generation cephalosporins, cefepime holds a leading position as a hospital antibiotic.
According to data obtained in vivo and from healthy volunteers, 100% of cefepime is absorbed into the systemic circulation when administered intramuscularly. This significantly optimizes therapy compliance and reduces treatment costs, as intravenous injections or infusions require qualified personnel and equipment and are not always convenient in general medical wards outside of intensive care units. Additionally, there is a risk of serious procedural complications.
The pharmaceutical product Cefepime powder for preparing a solution for intramuscular injection, manufactured by PJSC “Kraspharma,” is designed to optimize antibiotic therapy in hospital settings, bringing the benefits of modern antimicrobial drugs to broader clinical practice.
The drug is indicated for use in adults for:
- Lower respiratory tract infections, including pneumonia and bronchitis;
- Urinary tract infections, both complicated, such as pyelonephritis, and uncomplicated;
- Skin and soft tissue infections;
- Infections of the abdominal cavity, including peritonitis and biliary tract infections;
- Gynecological infections.
In children aged 12-18 years, the following indications are approved:
- Pneumonia;
- Urinary tract infections, both complicated, such as pyelonephritis, and uncomplicated;
- Skin and soft tissue infections.
To prevent the development of pain associated with intramuscular injection, the Cefepime powder for preparing a solution for intramuscular injection manufactured by PJSC “Kraspharma” is available in combination with a solvent – lidocaine injection solution 10 mg/ml, 3.5 ml in a glass ampoule.
